BioCentury | Nov 16, 2019
Company News

Management tracks: Lonza CEO to step down; plus Arrowhead, Insmed, Inozyme, Yukin, Pfenex, EyePoint, Verseau, Abingworth, CBC, Flagship, Diverse, Theragnostics,

Lonza Group Ltd. (SIX:LONN) CEO Marc Funk will leave the company in January for personal reasons. Chairman Albert Baehny will take on the CEO responsibilities on an interim basis. Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) said COO...
BioCentury | Jul 18, 2019
Financial News

Medicxi’s new €400M fund unites early, late stage investing

Medicxi’s newly closed third fund, its largest ever, will depart from the VC’s prior strategy by consolidating early and late stage investing into a single vehicle. Medicxi III will deploy €400 million ($451.2 million) across...
BioCentury | Jun 21, 2019
Finance

VC pair seeds cancer play Yukin, seeks preclinical readout

While Advent France Biotechnology and Medicxi are taking a wait-and-see approach with Yukin's kinase inhibitors targeting the NIK protein for cancer, the firms believe they could follow the biotech's €3.3 million ($3.7 million) seed round...
Items per page:
1 - 3 of 3
BioCentury | Nov 16, 2019
Company News

Management tracks: Lonza CEO to step down; plus Arrowhead, Insmed, Inozyme, Yukin, Pfenex, EyePoint, Verseau, Abingworth, CBC, Flagship, Diverse, Theragnostics,

Lonza Group Ltd. (SIX:LONN) CEO Marc Funk will leave the company in January for personal reasons. Chairman Albert Baehny will take on the CEO responsibilities on an interim basis. Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) said COO...
BioCentury | Jul 18, 2019
Financial News

Medicxi’s new €400M fund unites early, late stage investing

Medicxi’s newly closed third fund, its largest ever, will depart from the VC’s prior strategy by consolidating early and late stage investing into a single vehicle. Medicxi III will deploy €400 million ($451.2 million) across...
BioCentury | Jun 21, 2019
Finance

VC pair seeds cancer play Yukin, seeks preclinical readout

While Advent France Biotechnology and Medicxi are taking a wait-and-see approach with Yukin's kinase inhibitors targeting the NIK protein for cancer, the firms believe they could follow the biotech's €3.3 million ($3.7 million) seed round...
Items per page:
1 - 3 of 3